Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 6/22/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Raj Rai?

Raj Rai

Chief Executive Officer

Akorn , Inc.

HQ Phone:  (847) 279-6100

Direct Phone: (847) ***-****direct phone

Email: r***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Akorn , Inc.

1925 West Field Court Suite 300

Lake Forest, Illinois,60045

United States

Company Description

Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New Y...more

Web References(122 Total References)


Akorn - Investor Relations | Management

investors.akorn.com [cached]

Raj Rai
Chief Executive Officer Mr. Rai was appointed Interim Chief Executive Officer in June 2009, and appointed Chief Executive Officer in May 2010. He had been appointed Strategic Consultant to the Special Committee of the Board in February 2009, following the departure of our former President and Chief Executive Officer. Prior to joining Akorn, Mr. Rai was the President and CEO of Option Care, Inc., a leading provider of home infusion pharmacy and specialty pharmacy services, which was acquired by Walgreen Co. (now known as Walgreens Boots Alliance, Inc.) in August 2007. Mr. Rai previously served on the board of directors of SeQual Technologies Inc.


Akorn India

www.akornindia.com [cached]

Raj Rai
Chief Executive Officer, Akorn, Inc. Prior to joining Akorn, Raj Rai was president and CEO of Option Care, Inc. a leading pharmacy services provider of home infusion therapies and specialty pharmaceuticals Mr. Rai currently serves on the board of directors of Aciex Therapeutics an ophthalmic pharmaceutical company centered on developing products to treat ocular diseases


Akorn - Investor Relations | Press Release

investors.akorn.com [cached]

Raj Rai, Akorn's Chief Executive Officer, commented, "We are pleased with our performance in 2016.
Rai further added, "Our focus in 2017 and beyond remains consistent with our growth strategy of diversifying our portfolio, thus reducing product concentration through harvesting and replenishing our pipeline, deploying capital to consummate smart acquisitions through business development efforts and continuing to invest in our infrastructure.


Advanced Ocular Care - News

eyetubeod.com [cached]

"We are excited to bring our nonrefrigerated phenylephrine product back to the market shortly, and we expect a number of additional FDA approvals and product launches as we continue to progress through 2015," Akorn CEO Raj Rai said in the news release.


www.sec.gov

Raj Rai
Rai, Portwood and Kutinsky, or within the ninety-day period prior to or the twelve-month period In the event of a qualifying termination, Messrs Rai, Portwood, Bonaccorsi and Kutinsky would be entitled to receive: (a) a lump-sum payment equal to the product of three times (in the case of Mr. Rai) or two times (in the case of Messrs. Portwood, Bonaccorsi and Kutinsky) the sum of the executive's base salary and total eligible bonus amount; and (b) continued health and welfare benefits for three years (in the case of Mr. Rai) or two years (in the case of Messrs. Rai, Portwood, Bonaccorsi and Kutinsky also provide for payment of a pro-rata portion of the executive officer's total eligible bonus amount for the year in which such termination occurs. Raj Rai Rai, Portwood, Bonaccorsi and Kutinsky represent a lump-sum payment equal to the product of three times (in the case of Mr. Rai) or two times (in the case of Messrs. Rai, Portwood, Bonaccorsi and Kutinsky represent a lump-sum payment equal to the product of three times (in the case of Mr. Rai) or two times (in the case of Messrs. Rai, Portwood, Bonaccorsi or Kutinsky were to experience a qualifying termination of employment immediately following the closing of the merger, they would be eligible to receive an amount equal to the shortfall, if any, between the amount of such pro-rata bonus payment and a pro-rata bonus payment based on their total eligible bonus amount. Raj Rai Raj Rai The estimated amounts shown in this column represent continued health and welfare benefits for three years, in the case of Mr. Rai, two years, in the case of Messrs. As a condition to Fresenius Kabi and Merger Sub entering into the merger agreement, Dr. Kapoor, Mr. Rai, Mr. Bonaccorsi, Dr. Kutinsky and their shareholder affiliates executed and delivered to Fresenius Kabi the voting agreements, each dated April 24, 2017. At the close of business on the record date, Dr. Kapoor, Mr. Rai, Mr. Bonaccorsi, Dr. Kutinsky and their shareholder affiliates collectively beneficially owned and held voting power over 31,063,189 Company common shares (the "subject shares"), which represents approximately 24.9% of the voting power of the Company common shares. In connection with the execution and delivery of the voting agreements, Fresenius Kabi did not pay any of Dr. Kapoor, Mr. Rai, Mr. Bonaccorsi, Dr. Kutinsky and their shareholder affiliates any consideration in addition to the consideration they may receive pursuant to the merger agreement in respect of their Company common shares or, as applicable, any equity-based awards. Under the voting agreements, Dr. Kapoor, Mr. Rai, Mr. Bonaccorsi, Dr. Kutinsky and their shareholder affiliates agreed, among other things, to: Under the voting agreements, Dr. Kapoor, Mr. Rai, Mr. Bonaccorsi, Dr. Kutinsky and their shareholder affiliates irrevocably granted and appointed Fresenius Kabi, and any individuals designated in writing by Fresenius Kabi, as their proxy and attorney-in-fact to vote (A) in favor of the merger agreement and the transactions contemplated by the merger agreement and any related proposal in furtherance of the foregoing and (B) against any takeover proposal.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory